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S U M M A R Y
Pulmonary alveolar proteinosis can be secondary to inhaled dust exposure, malignancy, and chronic
pulmonary infections. However, pulmonary alveolar proteinosis secondary to extrapulmonary
aspergillosis has never been reported. We report herein a case of pulmonary alveolar proteinosis
secondary to invasive rhinocerebral aspergillosis. Neither immune modulators nor whole lung lavage
was applied during the treatment course. The severe respiratory distress subsided, hypoxia resolved, and
radiological inﬁltrates improved following the successful treatment of invasive rhinocerebral
aspergillosis alone.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Pulmonary alveolar proteinosis (PAP) is a rare disease with an
estimated annual incidence of 0.36 and prevalence of 3.70 cases
per million population.1 The disease is sub-grouped into three
types: congenital, idiopathic, and secondary. It is characterized by
excess accumulation of diastase-resistant, periodic acid-Schiff
(PAS)-positive granular lipoproteinaceous materials in the alveoli
and terminal bronchioli due to the impairment of surfactant
clearance by alveolar macrophages.2,3 Aspergillosis is a common
fungal infection of the paranasal sinuses in immunocompromised
hosts, such as those with diabetes and patients with leukemia.4
About 10% of the patients with invasive rhinal aspergillosis have
central nervous system (CNS) involvement.5 The mortality rate of
rhinocerebral aspergillosis approaches 90%, even with vigorous
surgery and antifungal chemotherapy.6
Secondary PAP accounts for less than 10% of the cases. Although
it has been known to be associated with opportunistic infections,
the development of PAP secondary to rhinocerebral aspergillosis in
an immunocompetent patient has never been reported. Our case
demonstrates the possible reversibility of secondary PAP after the
resolution of the underlying causative infection and highlights the
importance of early recognition in the treatment of rhinocerebral
aspergillosis.* Corresponding author. Tel.: +886 2 23123456x66842; fax: +886 2 23971412.
E-mail address: whsheng@ntu.edu.tw (W.-H. Sheng).
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A 71-year-old woman presented to our hospital due to
progressive exertional dyspnea and dry cough. She had also
suffered from intermittent pulsatile headache, gustatory change,
and postprandial vomiting for 2 months and had been treated for
bacterial sinusitis with tension headache at local hospitals. There
had been a 12-kg body weight loss within the past 10 months. The
patient was a non-smoker and had no co-morbidities.
On admission, the patient was conscious. Her temperature was
37 8C, pulse rate 66 beats per minute, respiratory rate 20 breaths
per minute, blood pressure 102/72 mmHg, and oxygen saturation
76–86% on room air. There was a left periorbital swelling, redness,
ptosis, and pupil dilatation. Left third, fourth and sixth cranial
nerve palsies were suspected. Chest examination disclosed ﬁne
crackles in the late inspiratory phase. Other physical and
neurological examinations were unremarkable. Hemogram and
blood biochemistry studies were within the normal range, except
for an elevated lactate dehydrogenase level (LDH; 707 U/l, normal
range 230–460 U/l). Serum tumor marker studies revealed
elevated carcinoembryonic antigen (CEA; 18.6 ng/ml, normal
<5.0 ng/ml) and carbohydrate antigen 19-9 (49.2, normal <37 U/
ml). Blood gas analysis showed hypoxemia on room air (PaO2 49.7
mmHg and PaCO2 35.5 mmHg). Autoimmune serology studies,
sputum cytology and cultures were negative.
A standing chest radiography (CXR) showed bilateral diffuse
interstitial inﬁltration and alveolar opacities (Fig. 1A). High-
resolution computed tomography (HRCT) of the chest revealedses. Published by Elsevier Ltd. All rights reserved.
Fig. 1. The initial chest X-ray showed bilateral diffuse interstitial inﬁltration and alveolar opacities (A), which resolved after the successful treatment of rhinocerebral
aspergillosis (B).
Fig. 2. The initial high-resolution computed tomography of the chest showed bilateral interlobular septal thickening on a background of ground-glass opacity in a crazy-
paving pattern (A), which improved signiﬁcantly after a 5-month antifungal therapy (B).
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glass opacity in a crazy-paving pattern (Fig. 2A). A pulmonary
function test disclosed a mild restrictive ventilatory defect with
severe impairment of carbon monoxide diffusing capacity (DLCO).
Brain magnetic resonance imaging (MRI) showed a 2.4  1.5 cm
inﬁltrativemass at the left orbital apex, with left cavernous and left
sphenoid sinus involvement. The tumor had a heterogeneous
contrast enhancement and was with intermediate signal on both
T1WI and T2WI images. Pulmonary alveolar proteinosis or
bronchioloalveolar carcinoma was the initial differential diagnosis
of the pulmonary lesions, and a sinonasal cancer, metastatic
cancer, neurogenic tumor, or infectious process was the ﬁrst
impression according to the brain imaging ﬁndings. A video-
assisted thoracoscopic lung biopsy and transethmoid sphenoid
sinus biopsy were arranged. Histopathology studies from the
pulmonary alveoli of two different lobes (right middle and right
lower lung) showed diffuse ﬁlling with PAS-positive granular
eosinophilic materials, indicating pulmonary alveolar proteinosis
(Fig. 3A). In addition, there was no evidence of pulmonary
infection, such as viral inclusion bodies, bacterial, fungal or
mycobacterial infections, found on pathological studies or
microbiological cultures. Results of sinus biopsy showed aggrega-tion of septated, sharp-angled branching hyphae, and rhinocer-
ebral aspergillosis was conﬁrmed by microbiological culture
(Fig. 3B).
Systemic antifungal therapy with liposomal amphotericin B (3–
5 mg/kg/day, adjusted according to renal function status) and oral
voriconazole (200 mg every 12 h) was administered after the tissue
diagnosis. Monthly transethmoid surgery for sphenoidectomy,
necrotic tissue debridement, and optic decompression was per-
formed in the following 2 months. Transnasal endoscopy-assisted
pus suctionwasdoneat two-week intervals. AbrainMRIwas carried
out every 4 weeks. Although the lesion initially progressed with
enlargement of size, occlusion of the left cavernous internal carotid
artery, and small parietal infarcts, the patient’s headache, vomiting,
and left eye ptosis subsided; ophthalmoplegia and orbital apex
syndrome improved; the gustatory abnormality recovered after 4
months. A brain MRI performed at the end of 5 months revealed a
decreased lesion size. The antifungal combination therapy was
administered for 5 months, followed by maintenance oral vorico-
nazole therapy (200 mg every 12 h).
Taking into consideration the severity of the invasive rhinocer-
ebral aspergillosis, no whole-lung lavage was performed through-
out the treatment course, despite the initial poor oxygenation
Fig. 3. (A) Histopathology of the lung showed diastase-resistant periodic acid-Schiff-positive eosinophilic granular material ﬁlling alveoli with intact interstitial architectures
(periodic acid-Schiff stain, original magniﬁcation66). (B) Histopathology of the sphenoid sinus biopsied specimen showed aggregation of septated, sharp-angled branching
hyphae (Grocott’s methenamine silver nitrate stain, original magniﬁcation 132).
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rated in the ﬁrst 2 months and she was dependent on a simple O2
mask (40–98%, 8–10 l/min) to maintain the SpO2 around 88–92%,
her condition stabilized later under systemic antifungal therapy. At
4 months of antifungal therapy, the patient could tolerate an O2
cannula (2 l/min) with the SpO2 around 95%. At the end of 5
months, the patient could tolerate room air well, with an SpO2
around 100% and the dyspnea resolved. A follow-up CXR (Fig. 1B)
and chest HRCT (Fig. 2B) at 5 months showed marked
improvement. Lung function tests revealed only mild impairment
of DLCO. The patient made an uneventful recovery.
3. Discussion
PAP is a disease of macrophage dysfunction presented by poor
phagocytosis of invasive pathogens. Pathophysiological mechan-
isms are involved in three ways: (1) by inhibiting ingestion of
phagocytic particles; (2) by decreasing the rate of ingestion; and
(3) by decreasing phagolysosome fusion. Alveolar macrophage
dysfunction may increase the risk of an opportunistic ‘pulmonary’
infection, such as pulmonary aspergillosis. To our knowledge, this
is the ﬁrst report of secondary PAP associated with invasive
extrapulmonary aspergillosis.
PAP usually presents with progressive dyspnea and a non-
productive cough. Pulmonary function tests typically reveal a
restrictive pattern with disproportionate reduction in diffusion
capacity. HRCT demonstrates thickening of interlobular septa with
a ground-glass background in a crazy-paving appearance. Diagno-
sis of PAP is based on histopathological study.3 Serum LDH, CEA,
cytokeratin 19,mucin KL-6, and surfactant proteins A, B, andDmay
be elevated in patients with PAP.7
Secondary PAP can be associated with hematological malig-
nancies, immunodeﬁciency disorders, inhaled chemicals, and
opportunistic infections, with hematological malignancies being
themost frequent.8–10 Resolution of PAP has been reported in these
patients whose hematological malignancies have been cured by
either chemotherapy or stem cell transplantation.11,12 Thus, it has
been hypothesized that secondary PAP can resolve following
treatment of the underlying disease.
The opportunistic organisms reported to be associatedwith PAP
include Nocardia, mycobacteria, cytomegalovirus, Pneumocystis
carinii, and Aspergillus.9,10,13 Most of these infections are conﬁned
to the lungs, attributed to alveolar macrophage dysfunction and
the nature of surfactant as being a good culturemedium.3 There are
few reports of disseminated atypical Mycobacterium infections
without pulmonary involvement14 and primary cerebellar nocar-
diosis15 in PAP patients. Moreover, all the reported cases in theliterature concerning PAP and aspergillosis are in patients with
hematological malignancies. The Aspergillus infections in these
have been limited to the lungs,16,17 except for one case in whom
systemic aspergillosis was deﬁned at autopsy.18
The clinical manifestations of rhinocerebral aspergillosis, such
as facial tenderness and nasal obstruction, are often subtle, and a
high degree of suspicion is needed to make an early diagnosis.19
Periorbital swelling, ophthalmoplegia, and orbital apex syndrome
signify orbital invasion; cavernous sinus and CNS involvement can
develop rapidly.19 Treatment of rhinocerebral aspergillosis
includes extensive surgical debridement, irrigation of the affected
cavity, and systemic antifungal therapy.20 It has been reported that
only 8.8% of patients with CNS involvement respond to amphoter-
icin B.21 Liposomal amphotericin B is an alternative and the dose
should exceed 3 mg/kg in CNS infections.22 The efﬁcacy of
caspofungin remains undetermined,23 while voriconazole has
been reported to be superior to amphotericin B and to have a good
CNS penetrating ability. According to a cohort study, 35% of the
patients partially responded to this drug and 31% of the patients
remained alive after 390 days.24
In the patient reported here, fungal sinusitis was not initially
disclosed and it progressed rapidly to invasive rhinocerebral
aspergillosis. She presented to our hospital with respiratory
distress, and physical examinations as well as imaging studies
disclosed the coexisting diseases. No evidence of pulmonary
aspergillosis was identiﬁed by chest images, histopathological
studies, or cultures. Surprisingly, the pulmonary condition
improved dramatically, both radiologically and clinically, follow-
ing the successful treatment of rhinocerebral aspergillosis.
Our case demonstrates that PAP can resolve following the
successful treatment of an underlying infectious disease. The case
also highlights the critical impact of clinical alertness for the early
diagnosis and management of rhinocerebral aspergillosis. Search-
ing for a possible underlying etiology of PAP should be emphasized
before it is categorized as idiopathic.
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